TCBP Financial Statements From 2010 to 2026
| TCBPDelisted Stock | USD 0.50 0.00 0.00% |
Check TC BioPharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TC BioPharm's main balance sheet or income statement drivers, such as , as well as many indicators such as . TCBP financial statements analysis is a perfect complement when working with TC BioPharm Valuation or Volatility modules.
TCBP |
TC BioPharm Holdings Company Return On Equity Analysis
TC BioPharm's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current TC BioPharm Return On Equity | -5.77 |
Most of TC BioPharm's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TC BioPharm Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, TC BioPharm Holdings has a Return On Equity of -5.7704. This is 75.93% lower than that of the Biotechnology sector and 84.17% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
TC BioPharm Holdings Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining TC BioPharm's current stock value. Our valuation model uses many indicators to compare TC BioPharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across TC BioPharm competition to find correlations between indicators driving TC BioPharm's intrinsic value. More Info.TC BioPharm Holdings is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the TC BioPharm's earnings, one of the primary drivers of an investment's value.About TC BioPharm Financial Statements
TC BioPharm shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although TC BioPharm investors may analyze each financial statement separately, they are all interrelated. The changes in TC BioPharm's assets and liabilities, for example, are also reflected in the revenues and expenses on on TC BioPharm's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
TC Biopharm Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Tc Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in TCBP Pink Sheet
If you are still planning to invest in TC BioPharm Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TC BioPharm's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |